评估α-Synuclein种子放大作为疾病进展标记物的作用:证据和不确定性
Daniel Belete1, Christian Mattjie1,2, Brook Huxford1
1Centre for Preventive Neurology, Wolfson Institute of Population Health, Faculty of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom.
Movement disorders clinical practice
|November 14, 2025
概括
α-synuclein种植放大试验 (α-synucleinSAA) 对帕金森病 (PD) 诊断有希望,但无法可靠地预测疾病的进展. 然而,α-synuclein SAA动态参数与REM睡眠行为障碍症状有关.
科学领域:
- 神经科学是一个神经科学.
- 生物标志物发现发现
- 临床诊断 临床诊断 临床诊断
背景情况:
- α-synuclein种植放大试验 (α-synuclein SAA) 是帕金森病 (PD) 的新兴诊断生物标志物.
- 对于α-同核素SAA对PD进展的预测价值仍然不确定.
- 这项研究调查了α-synuclein SAA与PD临床结果之间的关联.
研究的目的:
- 为了评估α-synuclein SAA和PD特定临床结果措施之间的关系.
- 为了确定α-synuclein SAA是否可以预测5年内的疾病进展.
- 探索α-synuclein SAA动态与非运动症状的关联.
主要方法:
- 分析了来自279名在帕金森病进展标记计划 (PPMI) 中的零星PD参与者的纵向数据.
- 主要结局包括MDS-UPDRS第三部分,MoCA和LEDD.
- α-同核素SAA动态参数被纳入回归模型,以评估它们对预测临床结果和RBDSQ问题-6的影响.
主要成果:
- 基线α-同核素SAA参数在5年随访时没有改善MDS-UPDRS Part III,MoCA或LEDD的预测模型.
- α-synuclein SAA 动态参数显著改善了适合 RBDSQ 问题-6 的模型.
- 更快的α-同核素SAA播种概况与更高的RBDSQ第6个问题得分有关,这表明与REM睡眠行为障碍的联系.
结论:
- 没有找到一致的证据将α-synuclein SAA与帕金森病进展联系起来.
- α-同核素SAA与REM睡眠行为障碍症状 (RBDSQ第6个问题) 有关.
- 需要进一步的研究来阐明影响α-synuclein聚合动力学和α-synucleinSAA在PD的预后作用的因素.
相关概念视频
01:37Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
03:03Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K
01:15Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
01:26Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K